Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning

Ndola Prata
Karen Weidert
Bixby Center for Population, Health and Sustainability, School of Public Health, University of California at Berkeley, Berkeley, CA, USA

Correspondence: Ndola Prata
School of Public Health, University of California at Berkeley, 229 University Hall, Berkeley, CA, 94720-7360, USA
Tel +1 510 643 4284
Email ndola@berkeley.edu

Background: A myriad of interventions exist to treat postpartum hemorrhage (PPH), ranging from uterotonics and hemostatics to surgical and aortic compression devices. Nonetheless, PPH remains the leading cause of maternal mortality worldwide. The purpose of this article is to review the available evidence on the efficacy of misoprostol for the treatment of primary PPH and discuss implications for health care planning.

Data and methods: Using PubMed, Web of Science, and GoogleScholar, we reviewed the literature on randomized controlled trials of interventions to treat PPH with misoprostol and non-randomized field trials with controls. We discuss the current knowledge and implications for health care planning, especially in resource-poor settings.

Results: The treatment of PPH with 800 µg of misoprostol is equivalent to 40 IU of intravenous oxytocin in women who have received oxytocin for the prevention of PPH. The same dose might be an option for the treatment of PPH in women who did not receive oxytocin for the prevention of PPH and do not have access to oxytocin for treatment. Adding misoprostol to standard uterotonics has no additional benefits to women being treated for PPH, but the beneficial adjunctive role of misoprostol to conventional uterotonics is important in reducing intra- and postoperative hemorrhage during cesarean section.

Conclusion: Misoprostol is an effective uterotonergic agent in the treatment of PPH. Clinical guidelines and treatment protocols should be updated to reflect the current knowledge on the efficacy of misoprostol for the treatment of PPH with 800 µg sublingually.

Keywords: PPH treatment, uterotonics, low-resource settings, cesarean section, retained placenta

Introduction
The world has witnessed reductions in maternal deaths in the past decade. Kassebaum et al.\(^1\) reported that the annual rate of change in the maternal mortality ratio was greater than −1% between 2003 and 2013, with the most substantial improvement from 2012 to 2013 at −3.3%. Many of the global gains in reducing maternal mortality can be attributed to developments in preventing and treating postpartum hemorrhage (PPH). In fact, the biggest absolute reduction was in maternal deaths due to hemorrhage.

Yet, PPH remains the most common cause of maternal death globally\(^2\) and has persisted in low-income countries with little change since 1990.\(^3\) This is in part due to the prevalence of home deliveries and limited access to life-saving uterotonics in these countries.\(^3–5\) Meanwhile, there is also evidence that the rate of retained placenta and PPH is increasing in higher-income countries.\(^6,7\)

PPH is often associated with the failure of the uterus to contract after delivery and categorized as blood loss of 500 mL or more following vaginal delivery or 1,000 mL...
after cesarean delivery. PPH is categorized as primary if it occurs within 24 hours of delivery and secondary if excessive blood loss occurs at 24 hours or more after delivery. The reality is that most cases are primary PPH and the time from beginning to death is considerably shorter than other major obstetric complications. Two factors have been identified as significantly affecting the potential for death from PPH. First, the initial hemoglobin (Hb) level of a woman affects her survival rate from PPH.10 The World Health Organization (WHO) defines anemia in pregnancy as Hb level <11 g/dL and reported that anemia among pregnant women in developing countries exceeds 50%.11 Recently, a strong correlation was found between low Hb (Hb <10) and the risk of PPH, as well as an association between severe anemia and emergency hysterectomy.12 Anemia can be detected during pregnancy, but early detection and treatment are not always promising in settings where limited access to quality antenatal care is further compounded by dietary deficiencies and concurrent medical disorders affecting iron absorption.12-14 The second factor that has been identified as contributing to mortality rates from PPH has more levers for influence, as it relates to access to a hospital with functioning facilities for the management of PPH, including blood banks and staff trained to diagnose and treat PPH. Although effective tools for the prevention and treatment of PPH are available, most are not feasible or available for use in the resource-poor countries, where many births still occur at home with untrained birth attendants.10 Meanwhile, the management of PPH is further complicated by timely diagnosis.10 Underestimation of blood loss by 100–150 mL is common when applying visual estimation.15 A study in 13 European countries showed that the use of a blood collector bag has not significantly reduced the rate of PPH, likely due to larger challenges in the management of PPH.16 However, better accuracy in the measurement of postpartum blood loss in developing countries might be an important first step toward improving case management.17

A recent multinational study led by the WHO to explore clinical practices, risks, and maternal outcomes associated with PPH included 275,000 births in 28 low- and middle-income countries. Of all the women included in the analysis, 95.3% received an uterotonic prophylaxis and 1.2% of women reported PPH; with the overall PPH death rate of 38 per 100,000 births. Not only is uterotonic treatment of PPH important in the reduction of adverse maternal outcomes but it can help avert more medical interventions, including the administration of intravenous (IV) fluids, additional drug therapy, blood transfusion, and surgery.18

The role of misoprostol, a prostaglandin E1 analog, in the prevention and treatment of PPH has evolved over time due to its long shelf life and multiple routes of administration, which make it more suitable for low-resource settings with limited skilled providers.19,20 As early as 2007, researchers were supporting the use of misoprostol for treating PPH in cases where other treatments are not available or not working, yet treating PPH in the community with misoprostol has lagged behind its widespread prophylactic use.9,21

The purpose of this article is to review the available evidence on the efficacy of misoprostol for the treatment of primary PPH. A brief historical perspective on the use of misoprostol for PPH and its potential role in treatment is presented as well as implications for management guidelines and health care planning, especially for low-income countries.

Data and methods
We first searched the Cochrane Database of Systematic Reviews for the most recent review of misoprostol for the treatment of PPH. We then searched PubMed for the literature on randomized controlled trials (RCTs) of interventions to treat PPH with misoprostol and reviewed relevant manuscripts not included in the most recent systematic review. Finally, we searched PubMed, Web of Science, and GoogleScholar for non-randomized field trials of interventions to treat PPH with misoprostol. The search covered the period from 2000 until 2015. The following search terms and various combinations were used: “postpartum hemorrhage”, “PPH”, “PPH treatment with misoprostol”, “misoprostol”, “randomized controlled trial”, “RCT”, “operations research”, “field trial”, “interventions to treat PPH”, “vaginal delivery”, “cesarean section”, and “retained placenta”.

Evidence on efficacy is based on the results from RCTs against either placebo or another uterotonic agent with or without active management of the third stage of labor with an uterotonic agent. Since we found only seven randomized controlled studies, we assess them individually. The last systematic review of misoprostol to treat PPH was published in 2005 and included only three of the seven reviewed RCTs. Even though it is not the primary aim of this review, we report on the efficacy of misoprostol for two conditions commonly associated with PPH, cesarean section and retained placenta. For these two conditions, we started with the more recent systematic review and meta-analysis, or Cochrane review published since 2000, and then reviewed individual RCT studies published after the systematic review. Results from non-randomized studies with controls or cohort studies are also reviewed. Current perspectives on PPH treatment are discussed including advances in drug regimens, gaps in current knowledge regarding PPH treatment with misoprostol, and challenges and opportunities for large-scale implementation in low-income countries.
Results
Misoprostol for the treatment of PPH

Over the past decade, key women’s health organizations have promoted the inclusion of misoprostol for the treatment of PPH. As early as 2006, the International Confederation of Midwives and the International Federation of Gynecology and Obstetrics (FIGO) recommended that misoprostol for the treatment of PPH may be appropriate for use in low-resource settings as a stand-alone treatment, in combination with oxytocin, and as a last resort for PPH treatment. At the same time, the American Congress of Obstetricians and Gynecologists included misoprostol in the list of uterotonic to be used as the first-line treatment for hemorrhage in the event of decreased uterine atony. A few years later, the Royal College of Obstetricians and Gynecologists agreed that misoprostol may be an appropriate alternative for PPH treatment in settings, where parenteral prostaglandins are not available or where there are contraindications. In 2012, FIGO published its guidelines for the treatment of PPH with misoprostol: “one dose of misoprostol 800 µg sublingually is indicated for the treatment of PPH when 40 IU IV oxytocin is not immediately available (irrespective of the prophylactic measures).”

In 2014, the Cochrane collaboration published a systematic review on the treatment for primary PPH. The review assessed the effectiveness and safety of any intervention used for the treatment of PPH. Of the ten RCTs reviewed spanning 4,052 women, seven investigated misoprostol in doses varying from 600 µg to 1,000 µg, using various routes of administration, including a combination of sublingual and rectal. The finding that seven out of ten studies were assessing the efficacy of misoprostol alone suggests that the role of misoprostol has been one of the most studied interventions in the treatment of PPH in recent decades. However, it was not until April 2015 that misoprostol was added to Essential Medicines WHO Model List (EML) for the treatment of PPH. The EML now recommends the use of misoprostol for the “prevention and treatment of PPH where oxytocin is not available or cannot be safely used”.

Evidence of efficacy of misoprostol for the treatment of PPH

Table 1 presents the results from all the published RCTs on the use of misoprostol for the treatment of primary PPH after vaginal deliveries. The last systematic review of misoprostol to treat PPH was published in 2005 and included three RCTs. However, given that only seven trials were available, we decided to show them individually in Table 1. RCTs have used multiple dose regimens and routes, in addition to controlling against placebo or another conventional uterotonic, oxytocin, and/or ergometrine. The first RCT was published in 2001 comparing 800 mg of misoprostol rectally to 5 IU oxytocin and 500 µg ergometrine intramuscular plus 10 IU oxytocin diluted in 500 mL normal saline IV infusion. Results from a relatively small sample size (n=32 in each arm) were promising, indicating that misoprostol is an effective therapy. In 2004, Hofmeyr et al published a placebo-controlled trial testing a high-dose misoprostol, but the study was underpowered to show significant differences. In the same year, a study by Walraven et al combined oral (200 µg) and sublingual (400 µg) routes of misoprostol and also showed the therapeutic potential of misoprostol against a placebo. Four years later, an RCT in Pakistan attempted to ascertain whether sublingual misoprostol had additional benefits to a standard oxytocin regimen. Although significant reductions in blood loss in the misoprostol group were reported, the study did not reach the intended sample size due to much lower PPH rate than expected. However, it was not until 2010 that pivotal evidence on the therapeutic potential of misoprostol became available from three RCTs. In a double-blind non-inferiority trial, Blum et al demonstrated that 800 µg of sublingual misoprostol is clinically equivalent to 40 IU IV oxytocin in women who have received prophylactic oxytocin during the third stage of labor. However, while the time to cessation and additional blood loss of 300 mL and 500 mL was equivalent, the number of women in the misoprostol group with >1,000 mL of additional blood loss was significantly higher (relative risk [RR]: 3.6; 95% confidence interval [CI]: 1.02–12.88). The women in the misoprostol group were also more likely to undergo intrauterine clinical exploration under anesthesia (RR: 1.66; 95% CI: 1.00–2.76). Results from a similar trial, but among women who have not been exposed to oxytocin during the third stage of labor, showed that misoprostol is slightly inferior to oxytocin. Authors conclude that in the absence of oxytocin, misoprostol might be an appropriate first-line treatment for PPH. The third RCT, published in 2010, assessed whether 600 µg of sublingual misoprostol could be used as an adjunct therapy to standard uterotonics. Results showed that when compared to a placebo, misoprostol does not offer additional benefits.

Table 2 shows the results from three non-randomized cohort studies with controls. These studies attempted to demonstrate application in home and hospital births. The study by Prata et al, the only community-based study with controls for the treatment of PPH, used a high dose (1,000 µg) of rectal misoprostol and demonstrated the potential use of misoprostol for PPH treatment in settings where women were...
Table 1: Randomized controlled studies of misoprostol for the treatment of PPH

<table>
<thead>
<tr>
<th>References</th>
<th>Study design/participants</th>
<th>Variable(s) of interest</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lokugamage et al</td>
<td>Single-blinded RCT to compare oxytocin and ergometrine combination to misoprostol</td>
<td>5 IU oxytocin and 500 µg ergometrine IM + 10 IU oxytocin diluted in 500 mL normal saline IV infusion compared to 800 µg rectal misoprostol</td>
<td>800 µg rectal misoprostol is effective in treating primary PPH Bleeding stopped within 20 minutes in 30 patients in the misoprostol group compared to 21 patients in the oxytocin + ergometrine group, with a 28.1% difference between the two groups ($P=0.01$) No significant difference in the clinical assessment of uterus contraction at 30 minutes or 60 minutes; misoprostol arm performed better at 120 minutes ($P=0.05$) Study was underpowered due to lower than expected incidence of primary outcome ($&gt;500$ mL of blood loss) in the placebo group Blood loss $\leq 500$ mL in 1 hour was 6/117 in the misoprostol group vs 11/120 in the placebo group ($RR: 0.56; 95% CI: 0.21–1.46$) Other proxy estimations of blood loss showed no significant differences between arms, including mean blood loss and Hb level on day 1 after birth (&lt;6 g/dL or blood transfusion Side effects significantly more frequent in the misoprostol group Five cases of serious morbidity in the misoprostol group, including three deaths</td>
</tr>
<tr>
<td>Hofmeyr et al</td>
<td>Double-blind RCT to determine side effects and effectiveness of high-dose misoprostol for the treatment of PPH</td>
<td>1,000 µg misoprostol (oral, 200 µg; sublingual, 400 µg; and rectal, 400 µg) compared to placebo</td>
<td>800 µg rectal misoprostol is effective in treating primary PPH Bleeding stopped within 20 minutes in 30 patients in the misoprostol group compared to 21 patients in the oxytocin + ergometrine group, with a 28.1% difference between the two groups ($P=0.01$) No significant difference in the clinical assessment of uterus contraction at 30 minutes or 60 minutes; misoprostol arm performed better at 120 minutes ($P=0.05$) Study was underpowered due to lower than expected incidence of primary outcome ($&gt;500$ mL of blood loss) in the placebo group Blood loss $\leq 500$ mL in 1 hour was 6/117 in the misoprostol group vs 11/120 in the placebo group ($RR: 0.56; 95% CI: 0.21–1.46$) Other proxy estimations of blood loss showed no significant differences between arms, including mean blood loss and Hb level on day 1 after birth (&lt;6 g/dL or blood transfusion Side effects significantly more frequent in the misoprostol group Five cases of serious morbidity in the misoprostol group, including three deaths</td>
</tr>
<tr>
<td>Waalraven et al</td>
<td>RCT to assess whether misoprostol is safe and confers additional benefits to routine treatment and after routine active management with uterotonics</td>
<td>600 µg misoprostol (oral, 200 µg and sublingual, 400 µg) compared to placebo</td>
<td>Measured average additional blood loss after medication was 325 mL (95% CI: 265–384 mL) after misoprostol and 410 mL (95% CI: 323–498 mL) after placebo Shivering and mild temperature were common in the misoprostol arm Indicators including additional blood loss $\leq 500$ mL (16.5% vs 28.4%) and $\geq 1,000$ mL (2.5% vs 6.2%) and use of additional uterotonics (3.8% vs 6.2%) were always lower in the misoprostol arm Study did reach the intended sample size due to much lower than expected PPH rate (&lt;2%) Women in the misoprostol group had significantly lower blood loss; blood loss $\leq 500$ mL (RR: 0.59; 95% CI: 0.12–2.99) Both postpartum drop in Hb and the use of additional interventions after treatment were lower in the misoprostol arm, but were not statistically significant Shivering and fever were commonly reported in the misoprostol arm Misoprostol is clinically equivalent to oxytocin when used to stop PPH in women who received prophylactic oxytocin during third stage of labor In the misoprostol arm, 89% of active bleeding controlled within 30 minutes vs oxytocin, 90% (RR: 0.99; 95% CI: 0.95, 1.04); additional blood loss of 300 mL or more after treatment (RR: 1.12; 95% CI: 0.92, 1.37) and additional uterotonics (RR: 0.86; 95% CI: 0.58, 1.28) Women in the misoprostol group were more likely to undergo intrauterine exploration under anesthesia; 9% vs 5% in the oxytocin arm (RR: 1.66; 95% CI: 1.00, 2.76)</td>
</tr>
<tr>
<td>Zuberi et al</td>
<td>Double-blind RCT to determine whether misoprostol provides additional benefits to a standard oxytocin regimen for the treatment of PPH</td>
<td>600 µg of sublingual misoprostol Standard PPH treatment with IV oxytocin was given to all women in need</td>
<td>800 µg rectal misoprostol is effective in treating primary PPH Bleeding stopped within 20 minutes in 30 patients in the misoprostol group compared to 21 patients in the oxytocin + ergometrine group, with a 28.1% difference between the two groups ($P=0.01$) No significant difference in the clinical assessment of uterus contraction at 30 minutes or 60 minutes; misoprostol arm performed better at 120 minutes ($P=0.05$) Study was underpowered due to lower than expected incidence of primary outcome ($&gt;500$ mL of blood loss) in the placebo group Blood loss $\leq 500$ mL in 1 hour was 6/117 in the misoprostol group vs 11/120 in the placebo group ($RR: 0.56; 95% CI: 0.21–1.46$) Other proxy estimations of blood loss showed no significant differences between arms, including mean blood loss and Hb level on day 1 after birth (&lt;6 g/dL or blood transfusion Side effects significantly more frequent in the misoprostol group Five cases of serious morbidity in the misoprostol group, including three deaths</td>
</tr>
<tr>
<td>Blum et al</td>
<td>Double-blind non-inferiority RCT in five countries to determine whether sublingual misoprostol is non-inferior to oxytocin in women who have received prophylactic oxytocin, with 6% margin of inferiority established as acceptable for clinical equivalence</td>
<td>800 µg sublingual misoprostol compared to 40 IU IV oxytocin in women who have received after prophylactic oxytocin</td>
<td>800 µg rectal misoprostol is effective in treating primary PPH Bleeding stopped within 20 minutes in 30 patients in the misoprostol group compared to 21 patients in the oxytocin + ergometrine group, with a 28.1% difference between the two groups ($P=0.01$) No significant difference in the clinical assessment of uterus contraction at 30 minutes or 60 minutes; misoprostol arm performed better at 120 minutes ($P=0.05$) Study was underpowered due to lower than expected incidence of primary outcome ($&gt;500$ mL of blood loss) in the placebo group Blood loss $\leq 500$ mL in 1 hour was 6/117 in the misoprostol group vs 11/120 in the placebo group ($RR: 0.56; 95% CI: 0.21–1.46$) Other proxy estimations of blood loss showed no significant differences between arms, including mean blood loss and Hb level on day 1 after birth (&lt;6 g/dL or blood transfusion Side effects significantly more frequent in the misoprostol group Five cases of serious morbidity in the misoprostol group, including three deaths</td>
</tr>
</tbody>
</table>
Other conditions associated with labor and delivery associated with PPH

Winkoff et al.10 Double-blind non-inferiority RCT to determine whether sublingual misoprostol is non-inferior to oxytocin for women not exposed to prophylactic oxytocin N=1978 women with PPH with N=488 in the misoprostol arm and N=490 in the oxytocin arm

800 µg sublingual misoprostol compared to 40 IU IV oxytocin in women

Misoprostol might be an appropriate first-line treatment for PPH in settings where oxytocin is not practical 90% of active bleeding controlled within 20 minutes in the misoprostol arm vs 96% in the oxytocin arm (RR: 0.94; 95% CI: 0.91, 0.98) 30% of women bled >300 mL in the misoprostol group vs 17% in the oxytocin group (RR: 1.78; 95% CI: 1.40, 2.26)

Twice as many women were given additional uterotonics in the misoprostol group (RR: 1.98; 95% CI: 1.31, 2.99) Findings do not support the use of misoprostol in addition to standard uterotonics for the treatment of PPH Blood loss of >500 mL within 60 minutes after randomization was 14% in both arms (RR: 1.02; 95% CI: 0.79, 1.32) No significant differences were found between arms in blood loss of >100 mL within 60 minutes or 90 minutes and median blood loss; Hb concentration of <80 g/L within 24 hours

Widmer et al.26 Double-blind RCT in five countries N=1422 women with PPH with N=705 in misoprostol arm and N=717 in placebo arm; both arms received standard uterotonics in addition to intervention

600 µg sublingual misoprostol compared to matching sublingual placebo Both arms received standard uterotonics in addition to intervention

The safety profile of misoprostol in obstetrics has long been established and is linked to the pharmacokinetic profile of E2 prostaglandin analog.5 In RCTs, misoprostol administered in treatment doses showed increased RR of side effects when compared to placebo. Although side effects were reported as transient and occurring in a small group of women, pooled data from a Cochrane review show actin increase in vomiting (RR: 3.12; 95% CI: 2.46–3.67), pyrexia of 38°C or more (RR: 1.35; 95% CI: 1.13–1.62), and postoperative hemorrhage showed that misoprostol and postoperative hemorrhage showed that misoprostol combined with oxytocin seems to be more efficacious than combined with oxytocin alone.3 The systematic review included 17 studies totaling 3,174 women. Seven studies assessed misoprostol plus oxytocin and seven assessed misoprostol alone.7-15 Subsequent RCTs found similar results when comparing misoprostol and oxytocin plus oxytocin alone.10,16 Results from a systematic review and meta-analysis evaluating the efficacy and safety of misoprostol for reducing intra- and postoperative hemorrhage has been investigated. Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties.7 A retrospective cohort study design.10 Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties.7 A retrospective cohort study design.

The remaining needed additional uterotonics in the inclusion of E2 prostaglandin analog.5 In RCTs, misoprostol administered in treatment doses showed increased RR of side effects when compared to placebo. Although side effects were reported as transient and occurring in a small group of women, pooled data from a Cochrane review show a significant increase in vomiting (RR: 3.12; 95% CI: 2.46–3.67), pyrexia of 38°C or more (RR: 1.35; 95% CI: 1.13–1.62), and postoperative hemorrhage showed that misoprostol combined with oxytocin seems to be more efficacious than combined with oxytocin alone.3 The systematic review included 17 studies totaling 3,174 women. Seven studies assessed misoprostol plus oxytocin and seven assessed misoprostol alone.7-15 Subsequent RCTs found similar results when comparing misoprostol and oxytocin plus oxytocin alone.10,16 Results from a systematic review and meta-analysis evaluating the efficacy and safety of misoprostol for reducing intra- and postoperative hemorrhage has been investigated. Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties.7 A retrospective cohort study design.10 Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties.7 A retrospective cohort study design.

Abbreviations: Hb, hemoglobin; IM, intramuscular; IV, intravenous; PPH, postpartum hemorrhage; RCT, randomized controlled trial; RR, relative risk; CI, confidence interval.

Efficacy of misoprostol for the treatment of postpartum hemorrhage with a lower dose and different route, confirmed the value of misoprostol in settings where oxytocin is not available. The use of high-dose rectal misoprostol was also assessed as an adjunct therapy to oxytocin compared to ergometrine using a retrospective cohort study design. Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties. A retrospective cohort study design. Results showed no significant differences between the two groups. Based on the results from the 2010 RCT, we now know that misoprostol has no adjunct therapeutic properties.
Table 2 Non-randomized studies on the treatment of PPH with misoprostol

<table>
<thead>
<tr>
<th>References</th>
<th>Study design/participants</th>
<th>Variable(s) of interest</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prata et al\textsuperscript{36}</td>
<td>Field intervention trial with control group to determine whether traditional birth attendants can diagnose and treat PPH. N=849 women enrolled, with N=454 in the intervention arm and N=395 in the nonintervention arm</td>
<td>1,000 µg of misoprostol rectally to all women delivering vaginally with blood loss of 500 mL or more. Referral to health facility in control sites</td>
<td>Eight women (2%) in the intervention area and 76 (19%) in the nonintervention area were referred to health facilities after delivery (OR: 0.1; 95% CI: 0.0–0.2). Of those referred, 1% from the intervention area and 95% from nonintervention area needed additional interventions due to PPH.</td>
</tr>
<tr>
<td>Baruah and Cohn\textsuperscript{37}</td>
<td>Retrospective cohort study with the control arm to assess the efficacy of rectal misoprostol as second-line therapy in the management of primary postpartum hemorrhage compared to methylergonovine. N=40 in the study arm and N=18 in the control arm</td>
<td>800–1,000 µg of misoprostol rectally following initial oxytocin therapy compared to 0.2 mg methylergonovine maleate intramuscularly following oxytocin therapy</td>
<td>No significant difference between the two arms in the need for blood transfusion (methylergonovine maleate group, 0%; misoprostol group, 12.5%; P=0.11), the need for third-line medical therapy (methylergonovine maleate group, 55.5%; misoprostol group, 55%; P=0.961) or the need for any surgical intervention (methylergonovine maleate, 22.2%; misoprostol 12.5%; P=0.51)</td>
</tr>
<tr>
<td>Okonofua et al\textsuperscript{38}</td>
<td>Cohort study design to investigate the efficacy of misoprostol sublingually to treat PPH in women experiencing PPH from uterine atony in three Nigerian hospitals. N=131 women with PPH due to atonic uterus</td>
<td>800 µg of misoprostol immediately after the loss of 500 mL or more blood</td>
<td>15.3% of women required additional treatment with IV oxytocin and ergometrine after the initial administration of sublingual misoprostol. 32.8% of women required blood transfusion, while all required IV infusion of saline and plasma expanders. No maternal deaths, but five neonatal deaths and two stillbirths. Results suggest that misoprostol is safe to be used in all levels of care for the primary treatment of PPH; there is a need for caution in recommending the use of misoprostol as first-line drug for the treatment of PPH in lower levels of care, since many women needed blood/blood products, the possibility of concomitant medical complications that providers need to address with women presenting with PPH, and need for follow-up care after severe PPH episode.</td>
</tr>
</tbody>
</table>

Abbreviations: IV, intravenous; PPH, postpartum hemorrhage; CI, confidence interval.
significant differences were found in the manual removal of placenta, severe PPH, need for blood transfusion, or other interventions.\(^3\) However, the authors noted that the quality of the evidence was low and called for much larger and sufficiently powered studies to make recommendations.

### Implications for management guidelines and health care planning

Although RCTs and non-randomized trials have used different doses and routes of administration, current evidence points to an optimal and effective dose regimen of 800 \(\mu\)g of sublingual misoprostol for the treatment of PPH, which was endorsed by FIGO.\(^2^5\) The safety profile of this dose and route is sufficient, but prostaglandin-related side effects such as shivering and vomiting may occur.\(^2^6\)

Misoprostol’s clinical equivalence to 40 IU IV oxytocin, when used for the treatment of PPH in women who have received a prophylactic dose of oxytocin during the third stage of labor, provides unique opportunities for low-resource settings. Where labor wards are ill-equipped to provide sufficient monitoring and quality IV infusion, service providers can use intramuscular oxytocin during the third stage of labor and sublingual misoprostol if a PPH diagnosis is established without hesitation. In addition, given the longer shelf life of misoprostol and relatively better stability in field conditions,\(^3^0\) health service planners, particularly those responsible for drug procurement, can adjust forecasting and purchasing of the drug assuming all estimated primary PPH cases will be treated with misoprostol, making it the first-line treatment.

Current evidence shows that in the absence of oxytocin prophylaxis during the third stage of labor, the drug of choice for the treatment of PPH should be 40 IU IV oxytocin. However, in settings where oxytocin is not available, sublingual misoprostol is an appropriate first-line treatment. This finding is of significance for settings where a large number of women deliver at home without a skilled provider or with a minimally trained one, as well as in settings where delivery begins at home and access to health facilities for referral when PPH is identified is limited due to the lack of transportation, road security at night, and other issues.\(^3\)

Contrary to expectations based on the evidence prior to 2010, findings from a multicenter RCT do not support the use of misoprostol in addition to standard uterotonic (oxytocin or ergometrine) for the treatment of primary PPH after vaginal deliveries.\(^3^5\) However, RCTs have demonstrated the opposite for cesarean deliveries.\(^4^0-4^2\) Thus, the adjunct role of misoprostol to conventional uterotonic is important in reducing intra- and postoperative hemorrhage.

In summary, current evidence on misoprostol efficacy is sufficient to move programs forward such that low-income countries, the ones with highest share of PPH-attributed burden of disease, can benefit from the ease of administration and storage of the drug. However, it is also in these contexts where the management of PPH cases is more challenging, despite knowledge of drug efficacy. For example, the efficacy from clinical trials assumes relatively accurate blood loss measurement, leading to a specific point in time when treatment is administered. Thus, standardizing clinical protocols with culturally appropriate ways to measure blood loss after delivery could increase program effectiveness for the treatment of PPH. Task shifting or sharing with providers at lower-level health centers and health posts, including community health workers, should also be considered, especially when referrals to health facilities are difficult.

In many countries, where access to misoprostol for PPH is being scaled up, providers could benefit from learning not just about prevention but also about the treatment for PPH, including clinical officers providing emergency cesarean sections in rural or district hospitals. Other ways to potentially increase program effectiveness to treat PPH in women who deliver at home would certainly include the use of community health workers and/or traditional birth attendants trained in the recognition of PPH and administration of misoprostol. However, more evidence in this area is still needed.

A Cochrane review with the objective of determining the safety and effectiveness of a system for advanced distribution of misoprostol for the prevention and treatment of PPH found insufficient evidence to support such a system.\(^4^5\) The review identified three studies, and none of them met the inclusion criteria – randomized or quasi RCTs. Thus, the conclusion is based on the lack of evidence rather than results from existing evidence. However, given the current knowledge of PPH-attributed mortality and the role of misoprostol to treat PPH, a randomized placebo-controlled experiment for advance distribution at community level might pose ethical concerns.

The comparison of misoprostol to placebo or to conventional uterotonic would allow programs to make informed decisions about the realm of interventions that are possible to implement in each setting according to provider level and health care system capacity. However, one important question still remains: can misoprostol be given for the treatment of PPH after its use for prevention during the third stage of labor? In addition, even though conventional uterotonic is more commonly used, what is the relative contribution of misoprostol compared to other interventions for PPH
treatment, such as the non-pneumatic antishock garment, hemostatic drugs, and surgical interventions? A review of these interventions concluded that more evidence is needed, including the best ways to treat women who do not respond to uterotonic.

Conclusion
Misoprostol is an effective therapy for primary PPH. Clinical guidelines and treatment protocols should be updated to reflect the current knowledge on the efficacy of 800 µg sublingual misoprostol for the treatment of PPH. However, improvements in PPH treatment, regardless of the uterotonic, should start with a timely and correct diagnosis that can lead to an appropriate case management. Women with prior exposure to prophylactic oxytocin, as well as those without exposure to oxytocin and in settings where oxytocin is not available, could all benefit from the therapeutic properties of this drug. Women undergoing cesarean section and at risk of PPH could also benefit from the efficacy of misoprostol in conjunction with oxytocin.

Disclosure
The authors report no conflicts of interest in this work.

References


